Ocuphire Pharma Investor Presentation Deck
8
Secondary Endpoint: Improvement in DCNVA Baseline vs. 1 Hour Post Nyxol+LDP
Nyxol + LDP had a Rapid Improvement on Near Vision for Many Patients
Percent of Subjects (%)
45%
40%
35%
30%
25%
20%
15%
10%
5%
0%
0%
7%
20/15
0%
12%
20/20
Binocular Photopic DCNVA
Nyxol + LDP
Improvement in Snellen Equivalent
84% 20/40 or Better Near Vision
68% 20/32 or Better Near Vision
0%
23%
20/25
0%
26%
20/32
VEGA-1 Phase 2 Trial
0%
Baseline
-16%
20/40
33%
Snellen Acuity
№%
20/50
1-Hour
40%
7%
20/63
23%
0%
20/80
Source: VEGA-1 TLR Table 14.2.24.1 Percent of Subjects with Photopic DCNVA by Time Point (PP Population)
2%
0%
20/100
Visual Acuity Chart
K CRHN
ZKDV C
HVORK
RHSON
KSVRH
HNK CD
NDVKO
DHOSZ
VRNDO
CZHKS
ORZSK
Before 20/63
After 20/32
Ocuphire
PHARMAView entire presentation